Jump to content

BI 1701963

From Wikipedia, the free encyclopedia

BI 1701963 is an investigational drug that blocks KRAS activation by binding to SOS1 proteins. The drug is thought to be effective in cancers with a KRAS mutation. It has been tested in clinical trials alone and in combination with adagrasib.[1][2][3]

References

[edit]
  1. ^ "Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)". www.cancer.gov. 23 June 2016. Retrieved 19 November 2023.
  2. ^ Johnson, M.L.; Gort, E.; Pant, S.; Lolkema, M.P.; Sebastian, M.; Scheffler, M.; Hwang, J.; Dünzinger, U.; Riemann, K.; Kitzing, T.; Jänne, P.A. (September 2021). "524P A phase I, open-label, dose-escalation trial of BI 1701963 in patients (pts) with KRAS mutated solid tumours: A snapshot analysis". Annals of Oncology. 32: S591–S592. doi:10.1016/j.annonc.2021.08.1046.
  3. ^ Hofmann, Marco H.; Lu, Hengyu; Duenzinger, Ulrich; Gerlach, Daniel; Trapani, Francesca; Machado, Annette A.; Daniele, Joseph R.; Waizenegger, Irene; Gmachl, Michael; Rudolph, Dorothea; Vellano, Christopher P.; Marotti, Marcelo; Vucenovic, Vitomir; Heffernan, Timothy P.; Marszalek, Joseph R.; Petronczki, Mark P.; Kraut, Norbert (1 July 2021). "Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan". Cancer Research. 81 (13_Supplement): CT210–CT210. doi:10.1158/1538-7445.AM2021-CT210.